P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis
Tomohiro Fujisaki1,2,3, Toshiki Kuno4,5, Alexandros Briasoulis6
1Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Morningside, and Mount Sinai West, New York, New York.
Texas Heart Institute Journal
|June 11, 2023
Summary
Prasugrel and ticagrelor showed similar outcomes for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients. Prasugrel demonstrated the highest likelihood of reducing major adverse cardiovascular events, warranting further investigation into optimal P2Y12 inhibitor selection.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Investigating P2Y12 inhibitors for non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
- Comparing prasugrel and ticagrelor efficacy and safety in NSTE-ACS patients.
Approach:
- Network meta-analysis of 11 clinical trials.
- Included 37,268 patients with NSTE-ACS.
Key Points:
- Prasugrel and ticagrelor showed comparable risks for ischemic and bleeding events.
- Prasugrel demonstrated the highest probability of reducing major adverse cardiovascular events (MACE).
- Compared to clopidogrel, both prasugrel and ticagrelor reduced cardiovascular death, with ticagrelor increasing bleeding risk.
Conclusions:
- Prasugrel and ticagrelor have similar risk profiles in NSTE-ACS.
- Prasugrel may offer superior efficacy for reducing MACE.
- Further research is needed for optimal P2Y12 inhibitor selection in NSTE-ACS.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
568
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
568
01:30Acute Coronary Syndrome III: Diagnostic Studies
11
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
11
01:27Coronary Artery Disease V: Interprofessional Care
11
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
11
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
575
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
575
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
22
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
22
01:27Peripheral Artery Disease III: Interprofessional Care
13
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
13